IMMUNOSUPPRESSIVE DRUG THERAPY IN LUPUS GLOMERULONEPHRITIS

强化、间歇性免疫抑制药物的疗效 治疗将在活动性狼疮患者中进行评估 在30个月的研究期间， 患者 肾活检证实活动性肾小球肾炎伴或不伴 肾功能恶化将用低剂量 剂量皮质类固醇，并随机接受（a）静脉内 甲基强的松龙每月一次，持续6个月，或（B）静脉注射 环磷酰胺每月一次脉冲给药，持续6个月，或（c）静脉给药 环磷酰胺冲击，每月一次，持续6个月，然后每3个月一次 在剩下的24个月的研究中。 在最后的24小时 在研究的3个月内，所有患者将接受低剂量泼尼松。 活动性疾病，表现为肾功能恶化， 蛋白尿增加或尿沉渣恶化，将接受治疗 增加泼尼松的剂量 将比较 肾功能、肾小球病理和药物治疗的良好结局 各治疗组在治疗结束时达到的相关毒性 第6和第30个研究月。 1981年4月至1987年7月 已有60多名患者参加了该方案。

The efficacy of intensive, intermittent immunosuppressive drug therapy will be evaluated in patients with active lupus glomerulonephritis over a 30 month study period. Patients with renal biopsy documented active glomerulonephritis with or without renal functional deterioration will be treated with low dose corticosteroids and randomized to receive (a) intravenous pulse methylprednisolone monthly for 6 months or (b) intravenous pulse cyclophosphamide monthly for 6 months or (c) intravenous pulse cyclophosphamide monthly for 6 months and then every 3 months for the remaining 24 months of the study. During the final 24 months of the study, all patients will receive low dose prednisone. Active disease, as manifested by renal functional deterioration, increased proteinuria or worsened urinary sediment, will be treated by increased prednisone. Comparison will be made of the number of favorable outcomes of renal function, glomerular pathology and drug related toxicities achieved by each treatment group at the end of the 6th and 30th study months. Between April 1981 and July 1987 there have been more than 60 patients entered into this protocol.